Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Irina Baldueva"'
Autor:
Anton Zozulia, Irina Baldueva, Anna Artemeva, Sergei Novikov, Anastasiia Muravtseva, Dmitrii Girdiuk, Natalia Emelianova, Elena Tiuriaeva, Elena Fedosova, Filipp Antipov, Andrei Arsenev, Mikhail Girshovich, Sergei Kanaev, Aleksei Beliaev
Publikováno v:
Problems in oncology. 67:797-803
Purpose. To study the influence of PD-L1 expression on the dynamics of immunological changes before and at different intervals after stereotactic body radiation therapy (SBRT) of metastatic lesions in patients with metastatic forms of solid tumors. M
Autor:
Anna Danilova, Tatiana Nekhaeva, Natalia Efremova, Aleksei Novik, Anton Zozulia, Georgii Gafton, Irina Baldueva
Publikováno v:
Problems in oncology. 67:815-828
The approach to the management of cancerous neoplasms, which aims to define the effective curative strategies in each patient, defines the requirement for the elaboration and use of modelling systems that replicate the structures and the biology of h
Autor:
Dmitrii Girdiuk, Natalia Emelianova, Elena Tyuryaeva, Aleksey Belyaev, Irina Baldueva, Andrei Arsenev, Anton Zozulia, Elena Fedosova, F. Antipov, Irina Korobova, Sergey Kanaev, Sergei V. Novikov, M. Girshovich
Publikováno v:
Problems in oncology. 67:391-396
Purpose. To evaluate immunological status in patients with metastatic forms of solid tumors before and at different intervals after stereotactic body radiation therapy (SBRT) of metastatic lesions depending on the dose and the number of irradiated me
Autor:
Diana Alaverdian, Alexandr N. Chernov, Irina Baldueva, Tatyana Nekhaeva, Elvira S. Galimova, O. V. Shamova
Publikováno v:
Problems in oncology. 67:20-28
In review discusses the phenomenon of drug resistance of GB in the context of the expression of ABC family transporter proteins and the processes of proliferation, angiogenesis, recurrence and death. The emphasis is on the identifying for molecular t
Publikováno v:
Problems in oncology. 67:7-12
The review discusses the pathogenetic mechanisms of the development of respiratory infection COVID-19 and the clinical use of cell technologies based on mesenchymal stem cells (MSCs). Due to the global pandemic of COVID-19/SARS- CoV-2 respiratory inf
Publikováno v:
Problems in oncology. 66:353-363
Selection of tolerated and toxic doses, schemes of therapy for new anticancer drugs, assessment of its toxicity, pharmacokinetics, metabolism, study of the mechanism of action and tumor sensitivity are carried out using models of human tumors in mice
Autor:
Anna Semenova, Irina Baldueva, Svetlana Protsenko, Yekaterina Anokhina, Aleksey Novik, A. Oganesian
Publikováno v:
Problems in oncology. 66:211-217
Immune checkpoint inhibitors are the most promising treatment option for many histological subtypes of malignant tumors, providing a long objective response and an increase in overall survival. Currently, there is growing evidence of the specific het
Autor:
Anton Zozulya, Elena Fedosova, F. Antipov, Sergey Kanaev, Sergey Novikov, Irina Baldueva, Natalya Yemelyanova, Aleksey Belyaev, A. Navoloka, Dmitry Viktorovich Girdyuk, Yelena Tyuryaeva
Publikováno v:
Problems in oncology. 66:277-282
Purpose. To evaluate immunological status in patients with metastatic forms of solid tumors before and at different intervals after stereotactic body radiation therapy (SBRT) of metastatic lesions. Materials and methods. A quantitative assessment and
Autor:
Andrey V. Panchenko, Vladimir N. Anisimov, Alexey G. Golubev, Alexey M. Belyaev, Stepan Kruglov, Mikhail Maydin, Anna S. Artemyeva, Irina Baldueva, Margarita L. Tyndyk, G. S. Kireeva
Publikováno v:
Chemotherapy. 65:42-50
Introduction: The effects of chemotherapy are known to depend on the time of administration. Circadian rhythms are disturbed in tumors and in tumor bearers. Agents involved in controlling the circadian rhythms (chronobiotics) potentially can modify t
Publikováno v:
Problems in oncology. 65:798-806
The progress in drug treatment of sarcomas is incredibly slow: primary, it is hindered by often developing resistance of tumors to standard chemotherapy with drugs in the maximum tolerated dosages. The clonal evolution of the tumor mass generates a h